Isentress (raltegravir) is a prescription drug used to treat HIV-1. Isentress can cause side effects that range from mild to serious. Examples include difficulty sleeping and headache. This article ...
Merck & Co., Inc. MRK recently announced that the FDA has approved Isentress HD, a new 1,200 mg once daily dose of its marketed drug Isentress (raltegravir), in combination with other anti-retroviral ...
Isentress (raltegravir) has potential interactions with other medications. For example, Isentress can interact with certain antacids and HIV medications. Isentress and Isentress HD are used with other ...
Isentress (raltegravir) is a brand-name drug that’s prescribed for HIV in adults and some children. Isentress comes as an oral tablet, a high dose oral tablet, a chewable tablet, and an oral ...
BELGRADE, Serbia--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of new exploratory pre-specified analyses from the ongoing STARTMRK ...
BOSTON--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new Phase III data showed that adult patients with HIV-1 infection maintained ...
Merck & Co., Inc. (NYSE: MRK) revealed efficacy, as well as, safety data in previously untreated adults with HIV-1 infection for its investigational once-daily formulation of ISENTRESS from the ...
Data from Week 48 previously showed that once-daily Isentress HD achieved the primary efficacy endpoint of non-inferiority vs. twice-daily Isentress. Merck announced new 96-week data from the Phase 3 ...
Raltegravir (as potassium) 100mg; per packet; pwd for oral susp; banana flavor. Pre-term neonates or <2kg: not recommended. Give first dose between 24–48hrs post birth if mother received raltegravir 2 ...
VIENNA, July 19 Abbott (NYSE: ABT) today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® ...
As expected, Merck & Co's Isentress, the firm’s new first-in-class AIDS drug, has received a recommendation for approval from a US regulatory advisory panel. As expected, Merck & Co’s Isentress, the ...
BOSTON--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new Phase III data showed that adult patients with HIV-1 infection maintained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results